臨床研究等提出・公開システム

Date of registration	Mar. 23, 2026
Last modified on	Mar. 23, 2026
Trial ID	jRCT1041250212

Scientific Title	An observational study on the therapeutic effects of GLP-1 receptor agonists and patients' dietary behavior patterns in clinical practice
Public Title	An observational study on the therapeutic effects of GLP-1 receptor agonists and patients' dietary behavior patterns in clinical practice

Contact for Scientific Queries	Name	Yabe Daisuke
	Affiliation	Gifu University Hospital
	Address	1-1, Yanagido,Gifu-shi,Gifu
	Telephone	+81-58-230-6000
	E-mail	daichan.yabechan@gmail.com
Contact for Public Queries	Name	Koide Yuya
	Affiliation	Gifu University Hospital
	Address	1-1, Yanagido,Gifu-shi,Gifu
	Telephone	+81-58-230-6000
	E-mail	xmndy633@yahoo.co.jp

Recruitment status	Complete

Study Design
Anticipated date of first enrollment		Mar. 23, 2026
Actual date of first enrollment		Sept. 01, 2021
Target sample size		180
Study Type		Observational



	purpose	treatment purpose
Key inclusion & exclusion criteria	Inclusion Criteria	Patients with type 2 diabetes who are judged by their physicians to be eligible for GLP-1 receptor agonists. In addition, patients who understand the purpose of the study and have given written consent.
	Exclusion Criteria	1) Patients who have difficulty in following the instructions of the principal investigator or sub-investigator 2) Patients who are judged by the principal investigator or sub-investigator to be unsuitable for this study
	Age Minimum	No limit
	Age Maximum	No limit

Health Condition(s) or Problem(s) Studied		type2 diabetes
Health Condition(s) Keyword		diabetes
Primary Outcome(s)		Change in HbA1c from baseline to 52 weeks after treatment initiation, stratified by baseline food preference and eating behavior.
Secondary Outcome(s)		Stratified by baseline food preference and eating behavior: Proportion achieving target HbA1c at 52 weeks Proportion achieving HbA1c <7.0% at 52 weeks Change in body weight from baseline to 52 weeks Change in body composition from baseline to 52 weeks Change in handgrip strength from baseline to 52 weeks Change in total energy intake and macronutrient intake (FFQ) from baseline to 52 weeks Change in urinary albumin (or urinary protein in patients with diabetic nephropathy stage 3 or higher) from baseline to 52 weeks

Primary Sponsor	none

Name of Certified Review Board	Gifu University Institutional Review Board
Address	1-1 Yanagido, Gifu 501-1194, Gifu, Gifu
Telephone	+81-58-230-6059
E-Mail	rinri@t.gifu-u.ac.jp
Approval Status	Approval
Date of approval	July. 30, 2021

Countries of Recruitment（Except Japan）	none